Everything below concerns FSFI desire score. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
== References == This article was adapted from the following source under a CC BY 4.0 license (2018) (reviewer reports): Cody J Hall; Tatiana P. Soares da Costa (2018). "Lysine: biosynthesis, catabolism and roles" (PDF). WikiJournal of Science. 1 (1): 4. doi:10.15347/wjs/2018.004. Wikidata Q55120301.
=== Pharmacokinetics === Venlafaxine is well absorbed, with at least 92% of an oral dose being absorbed into systemic circulation. It is extensively metabolized in the liver via the CYP2D6 isoenzyme to desvenlafaxine (O-desmethylvenlafaxine, now marketed as a separate medication named Pristiq), which is just as potent an SNRI as the parent compound, meaning that the differences in metabolism between extensive and poor metabolisers are not clinically important in terms of efficacy. Side effects, however, are reported to be more severe in CYP2D6 poor metabolisers. Steady-state concentrations of venlafaxine and its metabolite are attained in the blood within 3 days. Therapeutic effects are usually achieved within 3 to 4 weeks. No accumulation of venlafaxine has been observed during chronic administration in healthy subjects. The primary route of excretion of venlafaxine and its metabolites is via the kidneys. The half-life of venlafaxine is relatively short, so patients are directed to adhere to a strict medication routine, avoiding missing a dose. Even a single missed dose can result in withdrawal symptoms. Venlafaxine is a substrate of P-glycoprotein (P-gp), which pumps it out of the brain. The gene encoding P-gp, ABCB1, has the SNP rs2032583, with alleles C and T. The majority of people (about 70% of Europeans and 90% of East Asians) have the TT variant.
== January 2, 1982 (Saturday) == The Army of Guatemala, in a campaign by President Fernando Lucas Garcia, killed 35 civilians in the village of Pichec, in the Baja Verapaz Department near Rabinal, for their support of the Guerrilla Army of the Poor (Ejército Guerrillero de los Pobres). The killing was the third of the mostly Maya residents of Pichec, in less than nine weeks, with 32 men killed on November 1 and 30 more on November 22. Ahmad Fuad Mohieddin was selected to become the new Prime Minister of Egypt at the request of President Hosni Mubarak, who had held the position of both president and premier since the October 6 assassination of Anwar Sadat. In Denmark, the popular television series Matador broadcast its final episode, watched by 3.5 million viewers in a nation of 5.1 million people. The Clemson University Tigers football team finished in first place in both polls recognized by the NCAA for determining the U.S. major university football championship. In the AP poll of 49 sportswriters, Clemson received 977 points (based on 20 points for a first place vote, 19 for second place, etc.) and the Texas Longhorns 862 points. In the UPI poll of 37 coaches, Clemson had 547 points and the Pitt Panthers 472. In an NFL playoff game nicknamed the "Epic in Miami" as well as "The Game No One Should Have Lost", and ranked in a 2020 survey as the fourth greatest NFL game in the 20th century, the San Diego Chargers defeated the Miami Dolphins, 41 to 38, in overtime, after blowing a 24 to 0 lead in the first quarter.
== Chart performance == "Magic" charted most successfully in Canada, where it topped the RPM national singles chart on 19 July 1975, and received a gold certification. It climbed as far as number 11 on the UK Singles Chart and reached number 5 during the summer of 1975 in the US on the Billboard Hot 100.
== Regulation == As nickel can be harmful to skin, its use in daily products must be regulated. A safety directive has been in place in Europe since 2004. Denmark in 1980, and then shortly after the European Union (EU), enacted legislation that limited the amount of free nickel in consumer products that come in contact with the skin. This resulted in significantly decreased rates of sensitization among Danish children 0 to 18 years of age from 24.8% to 9.2% between 1985 and 1998, with similar reductions in sensitization throughout the EU. No such directive exists in the United States, but efforts are under way to mandate safe use guidelines for nickel. In August 2015, the American Academy of Dermatology (AAD) adopted a nickel safety position paper. The exact prevalence of Ni-ACD in the general population in the US is largely unknown. However, current estimates gauge that roughly 2.5 million US adults and 250,000 children have a nickel allergy, which costs an estimated $5.7 billion per year for treatment of symptoms. Loma Linda University, Nickel Allergy Alliance, and Dermatitis Academy created the first open access self-reported patient registry to record nickel allergy prevalence data in the US.[ref 23]
Sources: en.wikipedia.org
=== Classification === While traditional metrics often cited fixed percentages for sleep apnea types, recent population-based data suggest a different reality. Primary central sleep apnea (PCSA) is exceedingly rare, accounting for only 3.8% of all diagnosed CSA cases. Instead of rigid categories, modern sleep medicine now views sleep apnea as a dynamic spectrum, where true primary central cases are scarce, but central respiratory dysregulation frequently overlaps with obstructive events.
The history of pathology can be traced to the earliest application of the scientific method to the field of medicine, a development which occurred in the Middle East during the Islamic Golden Age and in Western Europe during the Italian Renaissance. Early systematic human dissections were carried out by the Ancient Greek physicians Herophilus of Chalcedon and Erasistratus of Chios in the early part of the third century BC. The first physician known to have made postmortem dissections was the Arabian physician Avenzoar (1091–1161). Rudolf Virchow (1821–1902) is generally recognized to be the father of microscopic pathology. Most early pathologists were also practicing physicians or surgeons.
== Research == Current research in regenerative medicine spans a continuous spectrum from fundamental cell biology to clinical translational engineering, focusing on deciphering and manipulating the signaling pathways that govern tissue morphogenesis, cellular differentiation, and scarless wound healing. Rather than merely managing chronic symptoms, active laboratory investigations aim to understand why adult mammalian tissues lose the regenerative capacities inherent in lower vertebrates and human embryonic states. Research strategies are broadly categorized into three interdependent vectors: cell-based therapies, which isolate and direct stem cell fates; biomaterial design, which engineers bioactive scaffolds to mimic the native extracellular matrix; and the delivery of localized biochemical cues, such as growth factors and gene-editing complexes, to orchestrate endogenous tissue repair. A major bottleneck in ongoing research is solving the scalability of functional vascularization, as complex engineered tissues cannot survive past the limits of oxygen diffusion without an integrated capillary network.
Center for the Advancement of Science in Space—operates the US National Laboratory on the ISS Dielectric wall accelerator Lawrence Berkeley National Laboratory List of US DOE National Laboratories Top 100 US Federal Contractors
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.